X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
iTOL-102 is our lead program that is developed Using our proprietary SA-FasL biotin-PEG microgel platform, which being developed as a potential cure for Type 1 Diabetes without the need for chronic immunosuppression.
Lead Product(s): Allogeneic Stem Cell-derived Pancreatic Islets
Therapeutic Area: Endocrinology Product Name: iTOL-102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kadimastem
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2023
Details:
The agreement aims for the commercialising of Folotyn (Pralatrexate), a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, in the People's Republic of China.
Lead Product(s): iTOL-102
Therapeutic Area: Endocrinology Product Name: iTOL-102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Northway Biotechpharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 01, 2023
Details:
Under the agreement, Kadimastem will supply its advanced cell product, IsletRx and iTolerance will provide its iTOL-100 immunomodulatory technology for the development of iTOL-102 (allogenic pancreatic islet cell) for the treatment of Type 1 Diabetes.
Lead Product(s): Allogenic Pancreatic Islet Cell
Therapeutic Area: Endocrinology Product Name: iTOL-102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kadimastem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 18, 2023
Details:
The funding will support the aforementioned technologies towards clinical application of iTOL-102, an allogeneic cell product intended to utilize stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells.
Lead Product(s): Allogenic Pancreatic Islet Cell
Therapeutic Area: Endocrinology Product Name: iTOL-102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BIRD Foundation
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 18, 2023
Details:
iTOL-100 acts to generate localized immune tolerance, allogeneic stem cell-derived pancreatic islets will be implanted in the body, which are capable of secreting insulin in response to sugar intake. It provides a potentially inexhaustible supply of insulin-producing cells.
Lead Product(s): iTOL-100
Therapeutic Area: Endocrinology Product Name: iTOL-100
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
iTOL-100, generates localized immune tolerance, allogeneic stem cell-derived pancreatic islets will be implanted in the body. These stem cells are potentially capable of secreting insulin in response to sugar intake, similar to how native pancreatic islet cells behave.
Lead Product(s): Allogeneic Stem Cell-derived Pancreatic Islets
Therapeutic Area: Endocrinology Product Name: iTOL-102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
DRI will assist in advancing potential of iTOL-100 platform technology is a biotechnology-derived Strepavidin-FasL fusion protein, mixed with a biotin-PEG microgel (SA-FasL microgel) to enable engraftment and long-term survival of transplanted insulin producing stem cells.
Lead Product(s): Allogenic Pancreatic Islets
Therapeutic Area: Endocrinology Product Name: iTOL-102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Diabetes Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 30, 2023
Details:
iTOL-101 developed for Type 1 Diabetes and in pre-clinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control blood glucose levels and restoration of insulin secretion without use of chronic immune suppression.
Lead Product(s): iTOL-101
Therapeutic Area: Endocrinology Product Name: iTOL-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
